Key facts
- This page summarizes Ibrahim B. Dagher's Form 4 filing for BRAINSTORM CELL THERAPEUTICS INC. (BCLI).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 07 Jan 2025, 16:11.
Ibrahim B. Dagher - 01 Jan 2025 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- BCLI
- Reported as of
- 01 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Jan 2025, 16:11:08 UTC
- Prior SEC filing
- 24 Jul 2024
- Next SEC filing
- 20 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ibrahim B. Dagher
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ibrahim B. Dagher filed Form 4 for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) on 07 Jan 2025.
Change
- Previous filing in this sequence was filed on 24 Jul 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BCLI
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +50,000
- Change %
- +297%
- Price
- $0.000000
- Shares after
- 66,849
- Date
- 01 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
BCLI
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 10,666
- Date
- 01 Jan 2025
- Ownership
- By the Reporting Person's Roth IRA
- Footnotes
- F2
BCLI
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,000
- Date
- 01 Jan 2025
- Ownership
- See Note
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock shall vest as to (i) 50% of the award on the six-month anniversary of the date of grant and (ii) the remaining 50% of the award shall vest on the eighteenth-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.
Footnote F2
Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024.
Footnote F3
Represents shares held in a custodial account under the Uniform Transfers to Minors Act for the benefit of the Reporting Person's child. The Reporting Person is the custodian of such account. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.